Wave Q3 Loss Widens to $61.9M; Cash Falls to $431.0M With No ATM Sales
WVE is trading near its 52-week low of $3.04 (13% above the low).
Summary
Wave's Q3 net loss widened to $61.9 million while cash and marketable securities fell to $431.0 million from $490.6 million at mid-year. Management says the balance covers at least twelve months, and no shares were sold under the $250.0 million ATM program in the quarter.
Key Events · Earnings and Guidance · WVE
-
Q3 Loss Widens on Higher R&D and G&A
Net loss was $61.9 million versus $53.9 million a year ago; R&D rose to $53.8 million from $45.9 million and G&A to $25.4 million from $18.1 million.
-
Cash Drops to $431.0 Million
Cash, cash equivalents and marketable securities fell from $490.6 million at June 30, 2026 to $431.0 million at September 30, 2026; management says this funds operations for at least the next twelve months.
-
No ATM Sales in the Quarter
Wave made no sales under its $250.0 million at-the-market equity program in the three and nine months ended September 30, 2026, versus $42.6 million of net ATM proceeds in the prior-year nine months.
-
GSK Milestone Adds $12.0 Million Revenue
GSK selected a candidate to move into its development pipeline in September 2026, triggering a $12.0 million milestone recorded as Q3 revenue; total Q3 revenue was $13.2 million.
Analysis · WVE · Life Sciences
Liquidity is the headline: Wave burned roughly $60 million in the quarter, ending September with $431.0 million in cash and marketable securities versus $490.6 million at June 30. The loss widened to $61.9 million from $53.9 million a year ago as R&D climbed to $53.8 million and G&A jumped to $25.4 million. Management still says the balance funds operations for at least the next twelve months, and the company did not touch its $250.0 million at-the-market program in the quarter — a sign it is not being forced to sell stock into a weak tape. The offsetting positive is commercial validation from GSK, which selected a candidate in September and triggered a $12.0 million milestone that was booked as Q3 revenue.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WVE was trading at $3.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $633.1M. The 52-week trading range was $3.04 to $21.73. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.